President's Message - July 2017

Dear Colleagues,

One of the pillars of the Society for Immunotherapy of Cancer’s (SITC) Strategic Plan is to “advance the science globally.” For more than 31 years, SITC has collaborated with international partners to further the field and application of cancer immunotherapy worldwide.

See what SITC has been up to around the globe:

SITC Members and International Advisory Committee
SITC recently formed the International Advisory Committee charged with building relationships with international cancer immunotherapy organizations, with the aim of providing collaborative international SITC educational activities to further stimulate immunotherapy research and global membership.

International Educational Collaborations
Already in 2017, SITC has reached more than 1,900 people internationally through collaborative educational programs. SITC continues to play an important role as the educational partner in the Immunotherapy of Cancer Conference (ITOC) series, which was presented by the Cancer Drug Development Forum (CDDF).

World Immunotherapy Council
SITC and the World Immunotherapy Council (WIC) will host the 2^nd World Immunotherapy Council Young Investigator Symposium during SITC’s 32^nd Annual Meeting & Pre-Conference Programs on Nov. 8, 2017. The program will provide the opportunity for young scientists and future leaders throughout the world to engage in scientific exchange to facilitate development and global dissemination of cancer immunotherapies. Learn more.

SITC Cancer Immunotherapy CONNECT and SITC Cancer Immunotherapy connectED
SITC bridges geographical distances through technology and develops targeted education to advance cancer immunotherapy. Through SITC CONNECT and SITC connectED, users around the world access the latest news, research and conversation through a community platform centered on cancer immunotherapy.

SITC Collaborations and Partnerships
Collaboration has been integral to SITC’s success as the source and resource for all things related to cancer immunotherapy. SITC works with global partners to further the field worldwide. Learn more.
Journal of ImmunoTherapy of Cancer

The Journal of ImmunoTherapy of Cancer (JITC) is an exceptional international journal exemplified by its 40 international editors and high global readership. Nearly half of the monthly visitors to JITC are from outside the U.S. Learn more.

SITC will continue to work with and address the concerns of our international members and collaborators around the globe to drive the field of cancer immunotherapy into the future. Thank you for your continued support.


Best wishes,

Lisa H. Butterfield, PhD

SITC President

President's Message - April 2017

 Dear Colleagues,

The Society for Immunotherapy of Cancer (SITC) on Monday, May 1 will launch SITC Cancer Immunotherapy connectED, its new online education tool for the greater cancer immunotherapy field. This education portal, part of SITC Cancer Immunotherapy CONNECT, provides educational resources and activities regarding current advances in cancer immunotherapy organized by stakeholder groups (patients, clinicians and researchers).

With the recent explosion of information related to cancer immunotherapy, there is a critical need for an unbiased educational resource destination where everyone can find the information they need, when they need it. SITC connectED will shape how we learn about cancer immunotherapy.

Utilizing a personalized learning system, SITC connectED identifies and delivers resources customized to each individual user. This portal highlights recent advances in the cancer immunotherapy field by providing educational activities using content from SITC and partner educational programs. SITC connectED bridges knowledge gaps by providing online educational opportunities in a convenient and easy to use platform.

Through SITC connectED, clinicians and patients can stay up-to-date on the most novel clinical applications of immunotherapy. Educational materials from live events will also be featured, allowing users to stay at the forefront of research in the immunotherapy field.

SITC connectED provides opportunities for medical professionals to earn continuing education credits (CME, CNE and CPE) and apply new concepts to clinical scenarios through engaging practice activities. Users will be able to utilize robust communication tools to share and collaborate with others in SITC CONNECT communities.

SITC connectED curates a variety of learning activities, including online classes, videos and webinars from world-renowned leaders in the field of cancer immunotherapy. This education portal will also provide opportunities for patients, caregivers and advocates to learn new information about the use of cancer immunotherapy to treat specific disease states.

Watch for an email on Monday providing a link to SITC connectED. I implore you all to experience this innovative learning portal.

Best wishes,

Lisa H. Butterfield, PhD

SITC President